McKesson Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -25

MCK Stock Falls Despite Q4 Earnings Beat, Sales Miss, Margins Up

AI-generated analysis

πŸ“Š McKesson reported Q4 adjusted EPS of $11.69, beating analyst estimates by 1.1% with a year-over-year bottom-line improvement of 15.5%.

πŸ’° The significant EPS growth was partially driven by a pre-tax credit related to the Rite Aid bankruptcy within the North American Pharmaceutical segment.

πŸ“‰ Total revenues of $96.3 billion missed the Zacks Consensus Estimate by 5.5%, despite a 6% year-over-year gain.

πŸ₯ Revenue growth was primarily fueled by increased prescription volumes in retail national accounts and expansion in oncology and specialty product distribution.

πŸ›‘ Lower contributions from branded pharmaceuticals partially offset the overall sales gains reported for the quarter.

πŸ’Έ Adjusted gross profit reached $3.86 billion, representing a 14% year-over-year increase and an expanded margin of 4.01%.

βš™οΈ Operating income improved to $1.97 billion, marking a 14.6% rise from the prior-year quarter with operating margins expanding by nearly 15 basis points.

πŸ“‰ After-hours trading saw shares fall 0.4% following mixed results where earnings beat but sales missed expectations.

πŸ’Ό McKesson operates under four new reportable segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions.

πŸ’Š The Oncology & Multispecialty segment saw revenue surge 31% to $12.71 billion, driven by provider solutions and recent acquisitions.

πŸ–₯️ Prescription Technology Solutions contributed significantly with revenues up 12% to $1.5 billion due to growth in logistics and technology services.

βš–οΈ Medical-Surgical Solutions revenues remained relatively flat at $2.87 billion, with gains from specialty drugs offset by lower ambulatory care contributions.

🀝 Management issued guidance for fiscal 2027, projecting adjusted EPS growth of 12-14% and total revenue growth between 5-9%.

πŸ”„ The company plans to complete the spin-off of its Medical-Surgical Solutions business in the second half of calendar 2027.

🌍 McKesson completed the divestiture of its retail and distribution businesses in Norway, further shaping its global portfolio.

Bullish Signals
  • McKesson reported fourth-quarter fiscal 2026 adjusted earnings per share (EPS) of $11.69, beating analyst estimates by 1.1%.
  • The bottom line improved significantly by 15.5% on a year-over-year basis to GAAP EPS of $13.71 versus $10.01 the prior year.
  • Fiscal 2026 adjusted EPS is projected to rise 18.3% to $39.11, demonstrating strong operational improvement across the business.
  • Revenues for fiscal 2026 are forecast to reach $403.43 billion, representing a robust 12.4% year-over-year growth.
  • The Oncology & Multispecialty segment delivered exceptional performance with revenues up 31% year over year and adjusted operating profit soaring 53%.
  • The North American Pharmaceutical segment saw adjusted operating profit increase by 11%, driven by growth in the distribution of specialty products.
  • Prescription Technology Solutions generated an uptick of 12% in revenues, fueled by increased demand for access solutions and third-party logistics services.
  • McKesson successfully raised its full-year guidance expectations, anticipating adjusted EPS to improve 12-14% to between $43.80 and $44.60.
  • The company's cash position strengthened materially with cash and cash equivalents increasing from $2.96 billion in Q3 to $3.98 billion at quarter-end.
  • Cash flow from operations remains highly robust, with cumulative net cash provided by operating activities totaling $6.16 billion compared to $6.09 billion the prior year.
  • The company expects Oncology and Multispecialty segment sales to grow rapidly at 14.5-18.5%, significantly outpacing other segments.
Risk Factors
  • McKesson's fourth-quarter revenues of $96.3 billion missed the Zacks Consensus Estimate by 5.5%, despite earnings per share beating expectations.
  • The company failed to meet market expectations on sales, leading to a decline of 0.4% in after-hours trading on May 7, and shares are already down 9.7% year-to-date compared to the S&P 500's gain of 8.6% in the same period.
  • Lower contributions from branded pharmaceuticals partially offset revenue growth, indicating ongoing headwinds in traditional high-margin product categories.
  • The Medical-Surgical Solutions segment only saw a 1% year-over-year revenue increase and is facing lower contributions from the ambulatory care channel.
  • McKesson plans to complete the spin-off of its Medical-Surgical Solutions business in the second half of calendar 2027, which may introduce complexity or dilution concerns depending on execution.
  • Guidance for fiscal 2027 expects operating profit growth in the Prescription Technology Solutions segment to range from 11% to 15%, while the Medical-Surgical Solutions segment projects flat-to-up 4% operating profit growth, suggesting muted outlooks for key segments.
Full Analysis
McKesson Corporation reported fourth-quarter fiscal 2026 adjusted earnings per share (EPS) of $11.69, surpassing the Zacks Consensus Estimate of $11.56 by 1.1% and showing a 15.5% year-over-year improvement in the bottom line. The enhanced EPS was primarily driven by strong operational performance across the business, including significant contributions from recent acquisitions within the Oncology & Multispecialty segment, while GAAP EPS rose to $13.71 compared to $10.01 in the prior year, boosted notably by a pre-tax credit related to the Rite Aid bankruptcy in the North American Pharmaceutical segment. Despite beating on earnings, McKesson's revenue of $96.3 billion missed the Zacks Consensus Estimate by 5.5%, even though the top line grew 6% year over year. This growth was fueled by increased prescription volumes from retail national account customers and expansion in the distribution of oncology and specialty products, including contributions from acquisitions that bolstered the Oncology & Multispecialty segment, which saw revenues jump 31% to $12.71 billion and adjusted operating profit surge 53% to $385 million. Other segments showed more moderate growth; North American Pharmaceutical revenues increased 3% to $79.12 billion driven by specialty products, while Prescription Technology Solutions grew 12% to $1.5 billion and Medical-Surgical Solutions saw only a 1% increase to $2.87 billion. The company highlighted margin expansion with adjusted gross profit reaching 4.01% of net revenues, an increase of nearly 28 basis points year over year, resulting in an adjusted operating income of $1.97 billion and an operating margin of 2.04%, up 15 basis points from the previous quarter. Cash and cash equivalents grew to $3.98 billion, reflecting cumulative net cash provided by operating activities of $6.16 billion, and McKesson reaffirmed its guidance for fiscal 2027, expecting adjusted EPS to improve 12-14% to between $43.80 and $44.60 alongside total revenue growth of 5-9%. The company also outlined specific segment projections, anticipating strong double-digit growth in Oncology and Multispecialty sales (14.5-18.5%) and significant profit improvements across all divisions, while noting the ongoing portfolio transformation toward a potential spin-off of the Medical-Surgical Solutions business expected by mid-2027.